Ian C. Clift, PhD, MLS(ASCP)CM has two bachelors degrees (Medical Technology and Neuroscience) and a PhD in Biomedical Sciences from the Mayo Clinic Graduate School. He has research and clinical laboratory experience and has published peer-reviewed science articles in well regarded journals (PNAS; Journal of Immunology; Lab Medicine). More recently he has devoted a significant effort to the development of health science coursework, training and curriculum at the undergraduate level; designing, developing, and directing two academic programs at the Indiana University’s South Bend campus.
His textbook, Clinical Immunodiagnostics: Clinical Principles and Practices was published officially on February 2021, however it was launched for pre-sales at the beginning of 2020 and seriously needs a revision to its section on coronaviruses.
He is currently interested in projects focused on personalized cancer research, oncology, and methods of disease investigation.
- Clift, I.C. (2021) “Clinical Immunodiagnostics: Laboratory Principles and Practices” Jones and Bartlett Learning, Burlington, MA. ISBN: 9781284173017
- Clift, I.C. (2021) “Funding the Next Generation of Cancer Therapies” Genetic Engineering & Biotechnology News, genengnews.com (https://www.genengnews.com/insights/funding-the-next-generation-of-cancer-therapies/) GEN 41(4)
- Clift, I.C. (2020) “Clinical laboratory role in viral pandemic response: Focus on COVID-19” Medical Research Archive 8(6)
- Clift, I.C. (2019) “Bispecific, Multispecific Antibodies Grapple with Cancer: Platforms for novel antibody constructs take hold in cancer immunotherapy development” Genetic Engineering & Biotechnology News, genengnews.com(https://www.genengnews.com/insights/bispecific-multispecific-antibodies-grapple-with-cancer/) GEN 39(2)
- Clift, I.C. (2015) “Diagnostic Flow Cytometry and the AIDS Pandemic” Lab Medicine 46(3): e59-e64
- Clift, I. C., A.O. Bamidele et al. (2014). “beta-arrestin1 and distinct CXCR4 structures are required for SDF-1 to down-regulate CXCR4 cell-surface levels in neuroblastoma” Mol Pharmacol. 85(4): 542-552
- Clift, I.C. (2016) “Driving Cancer Immunotherapy” Genetic Engineering & Biotechnology News, genengnews.com (http://www.genengnews.com/gen-articles/driving-cancer-immunotherapy/5726/) GEN 36(7).